Advanced search
Publication Cover
Journal of Chemotherapy Volume 34, 2022 - Issue 6
Submit an article Journal homepage
331
Views
1
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Papers

Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review

Mohammad Said Ramadana Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, ItalyORCID Iconhttps://orcid.org/0000-0002-1326-9696
ORCID Icon,
Raffaella Galloa Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
,
Marina Lugaràb Unit of Internal Medicine, Ospedale del Mare, Naples, Italy
,
Michele Gambardellac Infectious Diseases Unit, Ospedale S. Luca, Vallo della Lucania, Italy
,
Gabriella Olivab Unit of Internal Medicine, Ospedale del Mare, Naples, Italy
,
Lorenzo Bertolinoa Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
,
Roberto Andinid Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Naples, Italy
,
Nicola Coppolae Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
,
Rosa Zampinod Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Naples, Italy;f Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, ItalyORCID Iconhttps://orcid.org/0000-0003-2804-186X
ORCID Icon &
Emanuele Durante-Mangonia Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy;d Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Naples, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5381-3537
ORCID Icon show all
Pages 360-366 | Received 13 Oct 2021, Accepted 02 Dec 2021, Published online: 19 Dec 2021

References

  • Durante-Mangoni E, Gambardella M, Iula VD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020;56(4):106107.
  • David MZ, Dryden M, Gottlieb T, et al. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive pathogens: the shock of the new. Int J Antimicrob Agents. 2017;50(3):303–307.
  • Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48(2):137–143.
  • European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2019; [cited 2020]. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019#no-link
  • Durante-Mangoni E, Boccia F, Ursi MP, et al. Dalbavancin for infective endocarditis: a single Centre experience. J Chemother. 2021;33(4):256–262.
  • Thomas G, Henao-Martínez AF, Franco-Paredes C, et al. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents. 2020;56(3):106069.
  • Cooper CC, Stein GE, Mitra S, et al. Long-acting lipoglycopeptides for the treatment of bone and joint infections. Surg Infect (Larchmt). 2021;22(8): 771–779.
  • Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–214.
  • Matt M, Duran C, Courjon J, et al. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. J Glob Antimicrob Resist. 2021;25:341–345.
  • Vazquez Deida AA, Shihadeh KC, Preslaski CR, et al. Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy. Open Forum Infect Dis. 2020;7(8):ofaa293.
  • Wilke M, Worf K, Preisendörfer B, et al. Potential savings through single-dose intravenous dalbavancin in long-term MRSA infection treatment - a health economic analysis using german DRG data. GMS Infect Dis. 2019;7:Doc03.
  • Monteagudo-Martínez N, Solís-García Del Pozo J, Ikuta I, et al. Systematic review and meta-analysis on the safety of dalbavancin. Expert Opin Drug Saf. 2021;20(9):1095–1107.
  • Fiore V, De Vito A, Aloisio A, et al. Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases. Infect Dis (Lond). 2021;53(6):473–475.
  • Andreoni M, Bassetti M, Corrao S, et al. The role of dalbavancin for gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021;19(9):1125–1134.
  • Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019;47(6):1013–1020.
  • Almangour TA, Fletcher V, Alessa M, et al. Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report. Am J Case Rep. 2017;18:1315–1319.
  • Almangour TA, Perry GK, Terriff CM, et al. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019;93(3):213–218.
  • Bai F, Aldieri C, Cattelan A, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther. 2020;18(12):1271–1279.
  • Bryson-Cahn C, Beieler AM, Chan JD, et al. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019;6(2):ofz028.
  • Morata L, Cobo J, Fernández-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5):e02280-18. doi: 10.1128/AAC.02280-18.
  • Veve MP, Patel N, Smith ZA, et al. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive gram-positive infections. Int J Antimicrob Agents. 2020;56(6):106210.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.